Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Receivables - NetReceivables - Other
Ratios

China SXT Pharmaceuticals (SXTC) Receivables - Net (2018 - 2025)

China SXT Pharmaceuticals has reported Receivables - Net over the past 8 years, most recently at $100200.0 for Q3 2025.

  • For Q3 2025, Receivables - Net rose 133.04% year-over-year to $100200.0; the TTM value through Sep 2025 reached $100200.0, up 133.04%, while the annual FY2025 figure was $3.4 million, 157.36% up from the prior year.
  • Receivables - Net for Q3 2025 was $100200.0 at China SXT Pharmaceuticals, down from $1.3 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $4.5 million in Q1 2021 and troughed at -$303261.0 in Q3 2024.
  • A 5-year average of $1.8 million and a median of $1.3 million in 2024 define the central range for Receivables - Net.
  • Biggest five-year swings in Receivables - Net: surged 376.22% in 2022 and later crashed 315.6% in 2024.
  • Year by year, Receivables - Net stood at $697805.0 in 2021, then surged by 376.22% to $3.3 million in 2022, then crashed by 102.2% to -$72969.0 in 2023, then crashed by 315.6% to -$303261.0 in 2024, then surged by 133.04% to $100200.0 in 2025.
  • Business Quant data shows Receivables - Net for SXTC at $100200.0 in Q3 2025, $1.3 million in Q1 2025, and -$303261.0 in Q3 2024.